HealthDay - WEDNESDAY, Aug. 18 (HealthDay News) -- An experimental drug for metastatic melanoma prolonged median survival from 6.4 months to 10 months, which, although seemingly small, represents a significant extension of life for this normally intractable disease, a new study found.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.